Autoimmune hemolytic anemia medical therapy: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Autoimmune hemolytic anemia}} {{CMG}} '''Assosciate Editor(s)-In-Chief:''' Prashanth Saddala M.B.B.S Please help WikiDoc by adding mor...")
 
mNo edit summary
Line 24: Line 24:
{{Hematology}}
{{Hematology}}


[[Category:Hematology]]


{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}
[[Category:Mature chapter]]
[[Category:Disease]]
[[Category:Autoimmune diseases]]
[[Category:Coagulation system]]
[[Category:Blood disorders]]
[[Category:Needs content]]
[[Category:Hematology]]

Revision as of 16:19, 20 June 2016

Autoimmune hemolytic anemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Autoimmune hemolytic anemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Autoimmune hemolytic anemia medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Autoimmune hemolytic anemia medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Autoimmune hemolytic anemia medical therapy

CDC on Autoimmune hemolytic anemia medical therapy

Autoimmune hemolytic anemia medical therapy in the news

Blogs on Autoimmune hemolytic anemia medical therapy

Directions to Hospitals Treating Autoimmune hemolytic anemia

Risk calculators and risk factors for Autoimmune hemolytic anemia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Assosciate Editor(s)-In-Chief: Prashanth Saddala M.B.B.S

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Overview

Medical Therapy

Much literature exists regarding the treatment of AIHA. Efficacy of treatment depends on the correct diagnosis of either warm or cold type AIHA.

The aim of therapy may sometimes be to lower the use of steroids in the control of the disease. In this case, splenectomy may be considered, as well as other immunosuppressive drugs. Infection is a serious concern in patients on long-term immunosuppressant therapy, especially in very young children (less than two years).[1]

Warm type AIHA is usually a more insidious disease, not treatable by simply removing the underlying cause. First line therapy for this is usually with corticosteroids, such as prednisolone. Following this, other immunosuppressants are considered, such as rituximab, danazol, cyclophosphamide, azathioprine or cyclosporine.

Cold agglutinin disease is treated by avoiding the cold or sometimes with rituximab. Removal of the underlying cause is also important.

Paroxysmal cold hematuria is treated by removing the underlying cause, such as infection.

References

  1. Zecca M, Nobili B, Ramenghi U; et al. (2003). "Rituximab for the treatment of refractory autoimmune hemolytic anemia in children". Blood. 101 (10): 3857–61. doi:10.1182/blood-2002-11-3547. PMID 12531800. Unknown parameter |month= ignored (help)

Template:Hematology


Template:WikiDoc Sources